Tag: Aidan

New Delhi: The All India Drug Action Network (AIDAN) said it is shocked to learn of the SEC’s recommendation to grant REU approval to Bharat Biotech’s COVAXIN in “clinical trial mode” and “specially in the context of infection by mutant strains”. “In light of the intense concerns arising from the absence of efficacy data and […]